First test of HIV prevention pill for newborns begins
NCT ID NCT07055451
Summary
This study aims to find a safe dose of a three-drug combination pill (B/F/TAF) to prevent HIV infection in newborns whose mothers have HIV. It will enroll 16 full-term, uninfected newborns to check for side effects and measure how the drug moves through their bodies. The goal is to gather data to potentially use this medication to stop HIV transmission from mother to child.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Durban International Clinical Research Site, Enhancing Care Foundation
RECRUITINGDurban, 4013, South Africa
-
Family Centre for Research with Ubuntu (FAMCRU)
RECRUITINGCape Town, 7505, South Africa
-
Grady Health System - Ponce de Leon Center
RECRUITINGAtlanta, Georgia, 30308, United States
-
Perinatal HIV Research Unit (PHRU)
RECRUITINGGauteng, 1864, South Africa
-
Ronald Reagan UCLA Medical Center (inpatient hospital)
RECRUITINGLos Angeles, California, 90095, United States
-
St Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
-
WITS RHI Shandukani Research Centre
RECRUITINGJohannesburg, 2001, South Africa
Conditions
Explore the condition pages connected to this study.